Search
ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors
Co-Founder & CEO Avencia Sánchez-Mejías describes the science of how they achieve this. At ASGCT, the company is presenting the second generation of FiCAT, and offers examples of introducing 3 or 4 genes. Coverage brought to you by
May 13
BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform
Integra CEO Avencia Sánchez-Mejías and Caszyme CEO Monika Paulė discuss the deal and explain why Cas12l's small size gives it...
Nov 4, 2024
.png){kind=logo}